Amipryd, 100 mg: one tablet contains 100 mg of amisulpride (Amisulpridum).
Excipient with known effect: lactose monohydrate.
One Amipryd, 100 mg tablet contains 65 mg of lactose.
Amipryd is used in the treatment of acute and chronic schizophrenia with positive symptoms (such as: delusions, hallucinations, thought disorders, hostility and distrust) and (or) negative symptoms (such as: emotionlessness, emotional and social withdrawal), including also in patients with prevailing negative symptoms.
Hypersensitivity to the active substance or any of the excipients
listed in in sec. 6.1. Prolactin-dependent tumours, e.g. tumour of the pituitary gland such as prolactinoma and breast cancer. Pheochromocytoma. Dzieci przed okresem pokwitania. Children in pre-puberty. In combination with levodopa (see sec. 4.5).
Use in combination with medicinal products which may cause severe heart rhythm disorders such as torsade de pointes, including: class IA antiarrhythmic agents (such as quinidine, disopyramide); class III antiarrhythmic agents (such as amiodarone and sotalol); other drugs such as bepridile, cisapride, sultopride , thioridazin , methadone, intravenous erythromycin, intravenous vincamine, halofantrine , pentamidine, sparfloxacine, antifungal azoles (see sec. 4.5).
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
Amipryd, 100 mg: one tablet contains 100 mg of amisulpride (Amisulpridum).
Excipient with known effect: lactose monohydrate.
One Amipryd, 100 mg tablet contains 65 mg of lactose.
Amipryd is used in the treatment of acute and chronic schizophrenia with positive symptoms (such as: delusions, hallucinations, thought disorders, hostility and distrust) and (or) negative symptoms (such as: emotionlessness, emotional and social withdrawal), including also in patients with prevailing negative symptoms.
Hypersensitivity to the active substance or any of the excipients
listed in in sec. 6.1. Prolactin-dependent tumours, e.g. tumour of the pituitary gland such as prolactinoma and breast cancer. Pheochromocytoma. Dzieci przed okresem pokwitania. Children in pre-puberty. In combination with levodopa (see sec. 4.5).
Use in combination with medicinal products which may cause severe heart rhythm disorders such as torsade de pointes, including: class IA antiarrhythmic agents (such as quinidine, disopyramide); class III antiarrhythmic agents (such as amiodarone and sotalol); other drugs such as bepridile, cisapride, sultopride , thioridazin , methadone, intravenous erythromycin, intravenous vincamine, halofantrine , pentamidine, sparfloxacine, antifungal azoles (see sec. 4.5).
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
